Royalty Pharma plc Stock price

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
30.45 USD +0.73% Intraday chart for Royalty Pharma plc +0.13% +8.40%
Sales 2024 * 2.66B Sales 2025 * 2.95B Capitalization 13.6B
Net income 2024 * 1.06B Net income 2025 * 1.22B EV / Sales 2024 * 7.27 x
Net Debt 2024 * 5.75B Net Debt 2025 * 5.92B EV / Sales 2025 * 6.62 x
P/E ratio 2024 *
12.8 x
P/E ratio 2025 *
11.1 x
Employees -
Yield 2024 *
2.84%
Yield 2025 *
3.12%
Free-Float 95.04%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023. CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases MT
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M MT
Novartis wants to swallow Morphosys - access to beacon of hope DP
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16 MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024 CI
Transcript : Royalty Pharma plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM
Royalty Pharma Insider Sold Shares Worth $13,222,862, According to a Recent SEC Filing MT
Royalty Pharma plc and Royalty Pharma Holdings Ltd Enters into Amendment No. 3 to the Amended and Restated Revolving Credit Agreement CI
More news
1 day+0.73%
1 week+0.13%
Current month+0.36%
1 month-2.72%
3 months+8.71%
6 months+14.04%
Current year+8.40%
More quotes
1 week
30.03
Extreme 30.025
30.67
1 month
29.22
Extreme 29.215
30.73
Current year
27.17
Extreme 27.165
31.66
1 year
25.92
Extreme 25.92
37.31
3 years
25.92
Extreme 25.92
47.10
5 years
25.92
Extreme 25.92
56.50
10 years
25.92
Extreme 25.92
56.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 95-12-31
Director of Finance/CFO 42 09-12-31
Chief Tech/Sci/R&D Officer - 23-09-20
Members of the board TitleAgeSince
Founder 71 95-12-31
Director/Board Member 70 20-05-31
Director/Board Member 67 22-06-22
More insiders
Date Price Change Volume
24-03-27 30.45 +0.73% 1,424,648
24-03-26 30.23 -0.17% 1,541,953
24-03-25 30.28 +0.03% 1,321,137
24-03-22 30.27 -0.53% 1,591,081
24-03-21 30.43 +0.07% 2,172,869

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.45 USD
Average target price
45.4 USD
Spread / Average Target
+49.10%
Consensus
  1. Stock
  2. Equities
  3. Stock Royalty Pharma plc - Nasdaq